Plasma Glucagon-like Peptide-1 Levels and Acute Myocardial Infarction

Coronary Angiography Clinical Trial

Official title:

Prognostic Value of Plasma Glucagon-like Peptide-1 Levels in Acute Myocardial Infarction

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03129594
• Other study ID #: GLP1AMI
• Status: Completed
• Phase: N/A
• First received: April 23, 2017
• Last updated: October 3, 2017
• Start date: February 2013
• Est. completion date: February 2015

Study information

• Verified date: October 2017
• Source: Chinese PLA General Hospital
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

GLP-1(9-36) amide and (9-37), which was previously thought to be the inactive metabolite of GLP-1, also exerts cardioprotective effects. Direct administration of GLP-1(9-36) during reperfusion reduced ischaemic damage in isolated hearts and increased cGMP release, vasodilatation and coronary flow in AMI mouse model, one may speculate that total GLP-1 level may associate with adverse cardiovascular events in AMI patients, the hypothesis is therefore tested in this study.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 709
• Est. completion date: February 2015
• Est. primary completion date: February 2015
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• consecutive patients of acute AMI come to our department,absent of cardiogenic shock, and survival for at least 24 h after PCI treatment.

Exclusion Criteria:

• patients with cancer, and patients who were taking a DPP4 inhibitor or a glucagon-like peptide-1 (GLP-1) analogue

Related Conditions & MeSH terms

• Coronary Angiography
• Glucagon-like Peptide-1
• Infarction
• Myocardial Infarction

Intervention

Diagnostic Test:
• plasma glucagon-like peptide-1 levels
The plasma GLP-1 levels was determined by enzymatic assays.

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Chinese PLA General Hospital

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	all-cause mortality		The median follow-up was 29 months
Primary	cardiovascular mortality		The median follow-up was 29 months
Secondary	non-cardiovascular mortality		The median follow-up was 29 months
Secondary	Myocardial infarction		The median follow-up was 29 months
Secondary	heart failure readmission	readmission to any hospital due to diagnosed heart failure	The median follow-up was 29 months
Secondary	Stroke	defined using the World Health Organization criteria	The median follow-up was 29 months
Secondary	repeated revascularization	defined as repeated PCI or bypass grafting of not only infarct related artery	The median follow-up was 29 months